Rhythm Pharmaceuticals, Inc. (RYTM) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

19/25

Growth 5 Margin 4 Expansion 4 Platform 3 Financial 3

latest quarter score

Earnings Reports

19
Rhythm Pharmaceuticals (RYTM) Q2 2026: Incivary Launch Drives 19% Sequential Revenue Growth, Expanding Rare Disease Franchise
August 04, 2026
16
Rhythm Pharmaceuticals (RYTM) Q1 2026: HO Launch Drives 27% International Revenue Surge, Setting Up Global Expansion
May 05, 2026
15
Rhythm Pharmaceuticals (RYTM) Q4 2025: Operating Expenses to Rise 35% as Pipeline and HO Launch Drive Investment
February 26, 2026
15
Rhythm Pharmaceuticals (RYTM) Q3 2025: Patient Growth Up 10% as HO Launch Nears, Setting New Rare Disease Trajectory
November 04, 2025
16
Rhythm Pharmaceuticals (RYTM) Q2 2025: International Revenue Jumps 24% as HO Pipeline and Global Expansion Accelerate
August 05, 2025
14
Rhythm Pharmaceuticals (RYTM) Q1 2025: Global BBS Patient Base Up 14% as HO Launch Prepares for Acceleration
July 07, 2025

Browse all companies